A genome-wide analysis of more than 435,000 people has identified 29 genetic variants linked to problematic drinking, researchers at Yale University School of Medicine, and colleagues report May 25 in the journal Nature Neuroscience.
"The new data triple the number of known genetic risk loci associated with problematic alcohol use," said Yale's Joel Gelernter, the Foundations Fund Professor of Psychiatry and professor of genetics and of neuroscience, who is the senior author of the multi-institutional study.
The study includes a genome-wide analysis of people of European ancestry contained in four separate biobanks or datasets.
The researchers looked for shared genetic variants among those who met the criteria for problematic alcohol use, including alcohol use disorder and alcohol use with medical consequences.
These disorders are major contributors to a wide variety of medical problems worldwide.
The analysis found 19 previously unknown independent genetic risk factors for problematic alcohol use and confirmed 10 previously identified risk factors.
The meta-analysis of biobank data also included information on genetic risk factors for several psychiatric disorders. This information allowed researchers to study shared genetic associations between problematic drinking and disorders such as depression and anxiety.
They also found genetic heritability of these variants was enriched in the brain and in evolutionarily conserved regulatory regions of the genome, attesting to their importance in biological function.
Using a technique called Mendelian randomization, they were able to investigate how one genetically influenced trait affects another genetically linked trait.
This gives us ways to understand causal relations between problematic alcohol use traits such as psychiatric states, risk-taking behavior, and cognitive performance."
Hang Zhou, Study Lead Author and Associate Research Scientist in Psychiatry,Yale University
"With these results, we are also in a better position to evaluate the individual-level risk for problematic alcohol use," Gelernter said.
GLP-1 drugs, like semaglutide, lower risk of hospitalizations for alcohol use disorder